The Five-Year Clinical and Angiographic Follow-Up Outcomes of Intracoronary Transfusion of Circulation-Derived CD34+ Cells for Patients With End-Stage Diffuse Coronary Artery Disease Unsuitable for Coronary Intervention-Phase I Clinical Trial

Critical Care Medicine
Pei-Hsun SungHon-Kan Yip

Abstract

This study investigated the clinical and angiographic long-term outcomes of intracoronary transfusion of circulation-derived CD34+ cells for patients with end-stage diffuse coronary artery disease unsuitable for coronary intervention. A single-center prospective randomized double-blinded phase I clinical trial. Thirty-eight patients undergoing CD34+ cell therapy were allocated into groups 1 (1.0 × 10 cells/each vessel; n = 18) and 2 (3.0 × 10 cells/each vessel; n = 20). Those with end-stage diffuse coronary artery disease were unsuitable for percutaneous and surgical coronary revascularization. Intracoronary delivery of circulation-derived CD34+ cells. We prospectively evaluated long-term clinical and echocardiographic/angiographic outcomes between survivors and nonsurvivors. By the end of 5-year follow-up, the survival rate and major adverse cardio/cerebrovascular event were 78.9% (30/38) and 36.8% (14/38), respectively. During follow-up period, 31.6% patients (12/38) received coronary stenting for reason of sufficient target vessel size grown-up after the treatment. Endothelial function was significantly reduced in the nonsurvivors than the survivors (p = 0.039). Wimasis image analysis of angiographic findings showed that the...Continue Reading

References

Jul 13, 2001·JAMA : the Journal of the American Medical Association·R B D'AgostinoUNKNOWN CHD Risk Prediction Group
Jul 17, 2007·The Thoracic and Cardiovascular Surgeon·V GegouskovB Osswald
Jul 9, 2011·Circulation Research·Douglas W LosordoUNKNOWN ACT34-CMI Investigators
Mar 21, 2012·The Canadian Journal of Cardiology·E Marc JolicoeurPhilippe L L'Allier
Nov 17, 2015·Heart Failure Clinics·Molly Mack, Ambarish Gopal
Aug 6, 2016·JACC. Cardiovascular Interventions·Thomas J PovsicUNKNOWN RENEW Investigators

❮ Previous
Next ❯

Citations

Aug 23, 2020·Biomedicines·Kudrat Rakhimov, Tommaso Gori
Oct 11, 2020·International Journal of Molecular Sciences·Pawan FarisFrancesco Moccia
Jan 11, 2020·JACC. Cardiovascular Interventions·Guglielmo GalloneFrancesco Giannini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cardiac Regeneration

Cardiac regeneration enables the repair of irreversibly damaged heart tissue using cutting-edge science, including stem cell and cell-free therapy. Discover the latest research on cardiac regeneration here.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.